Skip to main content
Caplight Logo









GlycoMira Therapeutics

GlycoMira Therapeutics

Private
Salt Lake City, UtahHealthcare & Life Scienceshttps://www.glycomira.com/

Last Round

Early Funding

Jan 1, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

GlycoMira Therapeutics is a biopharmaceutical company developing a novel class of innate immune system modulators based on naturally occurring polysaccharides for the treatment of cancer and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

biopharmaceuticalsmall-molecule therapeuticsimmune modulatorSAGE technologytumor microenvironmentoncologysupportive careoral mucositisdrug discoveryclinical-stage biotechbiotech startupglycosaminoglycanSBIR grantsdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GlycoMira Therapeutics Comparables

Compare GlycoMira Therapeutics with similar companies based on industry and business-model similarity.

GlycoMira Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cantex Pharmaceuticals
79%
Enzychem Lifesciences
79%
Lipella Pharmaceuticals Inc.
76%

GlycoMira Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJan 1, 2025

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Web traffic grew 58% MoM (from 317 to 500 monthly visitors)

  • May 17, 2026

    Web traffic grew 66% MoM (from 590 to 979 monthly visitors)

GlycoMira Therapeutics Filings

Explore SEC and related filing metadata, where available.

GlycoMira Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GlycoMira Therapeutics's valuation, stock price, and market status.

Is GlycoMira Therapeutics a public or private company?

GlycoMira Therapeutics is a private company.

What is the current stock price of GlycoMira Therapeutics?

GlycoMira Therapeutics is a private company with no public stock price. Caplight tracks GlycoMira Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is GlycoMira Therapeutics worth (valuation)?

Valuation information for GlycoMira Therapeutics is not publicly available.

Can I buy GlycoMira Therapeutics stock?

GlycoMira Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GlycoMira Therapeutics's last funding round?

GlycoMira Therapeutics's most recent funding round was Early Funding on January 1, 2025.

Who are the main investors in GlycoMira Therapeutics?

Investor information for GlycoMira Therapeutics is not publicly disclosed.

Will GlycoMira Therapeutics IPO soon?

No public IPO plans have been announced for GlycoMira Therapeutics.

How can I track GlycoMira Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GlycoMira Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSalt Lake City, Utah
Employee Range6
Year Founded2008
Last FundingJan 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?